SCHEMBL1624852

SCHEMBL1624852

O=C(O)c1ccc(N=Nc2ccc(O)c(C(=O)O)c2)cc1O

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.85
KMT2A Q03164 3/20 0.85
KDR P35968 2/20 0.85
PDE4A P27815 1/20 0.85
BLVRB P30043 1/20 0.85
HTT P42858 1/20 0.85
TDP1 Q9NUW8 4/20 0.74
THRB P10828 2/20 0.74
RECQL P46063 2/20 0.74
APP P05067 1/20 0.74
BLM P54132 1/20 0.74
ALDH1A1 P00352 5/20 0.64
HSD17B10 Q99714 3/20 0.64
CYP2C19 P33261 3/20 0.64
PTGS2 P35354 3/20 0.64
PHLPP2 Q6ZVD8 2/20 0.64
TSHR P16473 2/20 0.64
CYP2C9 P11712 2/20 0.64
PTGS1 P23219 1/20 0.64
CYP2D6 P10635 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3386039 1.00 MEN1 (0.85) MEN1KMT2AKDRPDE4ABLVRB
SCHEMBL1624756 0.92 MEN1 (0.70) MEN1KMT2AKDRPDE4ABLVRB
Olsalazine SCHEMBL29861404 0.92 MEN1 (1.00) MEN1KMT2AKDRPDE4ABLVRB
SCHEMBL26730466 0.92 MEN1 (0.70) MEN1KMT2AKDRPDE4ABLVRB
Olsalazine SCHEMBL25118 0.92 MEN1 (1.00) MEN1KMT2AKDRPDE4ABLVRB
SCHEMBL3385330 0.92 MEN1 (0.70) MEN1KMT2AKDRPDE4ABLVRB
Olsalazine SCHEMBL25119 0.92 MEN1 (1.00) MEN1KMT2AKDRPDE4ABLVRB
Olsalazine SCHEMBL29378994 0.92 MEN1 (1.00) MEN1KMT2AKDRPDE4ABLVRB
Olsalazine SCHEMBL29385751 0.92 MEN1 (1.00) MEN1KMT2AKDRPDE4ABLVRB
Olsalazine SCHEMBL2628413 0.92 MEN1 (1.00) MEN1KMT2AKDRPDE4ABLVRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1993517-B1 MODIFIED RELEASE FORMULATIONS AND METHODS OF TREATING INFLAMMATORY BOWEL DISEASE ALLERGAN PHARMACEUTICALS INT LTD (IE) 2019-05-08 EP claimed
EP-1663253-B1 FORMULATIONS CONTAINING SALICYLATES AND THEIR USE FOR TREATING INFLAMMATORY BOWEL DISEASE AGI THERAPEUTICS RES LTD (IE) 2010-12-01 EP claimed
US-7825106-B2 Modified release formulations and methods of treating inflammatory bowel disease AGI THERAPEUTICS LTD. (IE) 2010-11-02 US claimed
US-7737133-B2 Formulations and methods of treating inflammatory bowel disease AGI THERAPEUTICS LTD. (IE) 2010-06-15 US claimed
EP-1993517-A2 MODIFIED RELEASE FORMULATIONS AND METHODS OF TREATING INFLAMMATORY BOWEL DISEASE AGI Therapeutics Research Limited (IE) 2008-11-26 EP claimed
WO-2007119177-A2 MODIFIED RELEASE FORMULATIONS AND METHODS OF TREATING INFLAMMATORY BOWEL DISEASE AGI THERAPEUTICS RESEARCH LIMITED (US) 2007-10-25 WO claimed
US-20060223787-A1 Modified release formulations and methods of treating inflammatory bowel disease ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) 2006-10-05 US claimed
US-20050090473-A1 Formulations and methods of treating inflammatory bowel disease ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) 2005-04-28 US claimed
EP-0133423-B1 USE OF 4,5'-AZO-BIS-SALICYLIC ACID FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY DISORDERS IN THE INTESTINE PHARMACIA AB (SE) 1987-11-25 EP claimed
US-4591584-A ANTIINFLAMMATORY AGENTS; GASTRO INTESTINAL DISORDERS PHARMACIA AB (SE) 1986-05-27 US claimed
EP-0145777-A1 AZO-BIS-SALICYLIC ACID AND SALT THEREOF, PHARMACEUTICAL FORMULATIONS AND USES OF SAID ACID AND SALT, AND PRODUCTION OF THE ACID PHARMACIA AB (SE) 1985-06-26 EP claimed
EP-0133423-A1 Use of 4,5'-azo-bis-salicylic acid for the manufacture of a medicament for the treatment of inflammatory disorders in the intestine PHARMACIA AB (SE) 1985-02-20 EP claimed
WO-1985000013-A1 AZO-BIS-SALICYLIC ACID AND SALT THEREOF, PHARMACEUTICAL FORMULATIONS AND USES OF SAID ACID AND SALT, AND PRODUCTION OF THE ACID PHARMACIA AB (SE) 1985-01-03 WO claimed
EP-1993517-B1 MODIFIED RELEASE FORMULATIONS AND METHODS OF TREATING INFLAMMATORY BOWEL DISEASE ALLERGAN PHARMACEUTICALS INT LTD (IE) 2019-05-08 EP disclosed
US-7928092-B2 Formulations and methods of treating inflammatory bowel disease AGI THERAPEUTICS LTD. (IE) 2011-04-19 US disclosed
EP-1663253-B1 FORMULATIONS CONTAINING SALICYLATES AND THEIR USE FOR TREATING INFLAMMATORY BOWEL DISEASE AGI THERAPEUTICS RES LTD (IE) 2010-12-01 EP disclosed
EP-0133423-A1 Use of 4,5'-azo-bis-salicylic acid for the manufacture of a medicament for the treatment of inflammatory disorders in the intestine PHARMACIA AB (SE) 1985-02-20 EP disclosed
EP-0133423-A1 Use of 4,5'-azo-bis-salicylic acid for the manufacture of a medicament for the treatment of inflammatory disorders in the intestine PHARMACIA AB (SE) 1985-02-20 EP disclosed
WO-1985000013-A1 AZO-BIS-SALICYLIC ACID AND SALT THEREOF, PHARMACEUTICAL FORMULATIONS AND USES OF SAID ACID AND SALT, AND PRODUCTION OF THE ACID PHARMACIA AB (SE) 1985-01-03 WO disclosed
WO-1985000013-A1 AZO-BIS-SALICYLIC ACID AND SALT THEREOF, PHARMACEUTICAL FORMULATIONS AND USES OF SAID ACID AND SALT, AND PRODUCTION OF THE ACID PHARMACIA AB (SE) 1985-01-03 WO disclosed